Opus Genetics ( (IRD) ) has shared an announcement.
Opus Genetics, Inc. has amended and restated its executive employment agreements with its CEO, Dr. George Magrath, and CFO, Nirav Jhaveri, enhancing severance packages in connection with a ‘Change in Control’. These changes, effective January 17, 2025, include increased cash severance payments and extended COBRA coverage, reflecting Opus Genetics’ commitment to securing leadership stability during transitional corporate events.
More about Opus Genetics
YTD Price Performance: -8.73%
Average Trading Volume: 225,523
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $36.3M
For a thorough assessment of IRD stock, go to TipRanks’ Stock Analysis page.